hsa-mir-183: Hsa-mir-183 is a microRNA that has been found to have frequent aberrant DNA methylation at its promoter [PMC5340808]. In a study, 791 miRNAs that interacted with 137 downregulated "seeds" were analyzed, and it was discovered that 22 miRNAs, including hsa-mir-183, were upregulated and could predict gene expression regulation in prostate cancer (PCa) [PMC8426106]. The other upregulated miRNAs identified in the study were hsa-mir-500a, hsa-mir-17, hsa-mir-425, hsa-mir-20b, hsa-mir-508, hsa-mir-3074, hsa-mir-106a, hsa-mir-25, hsa-mir-18a, hsa-mir-342, hsa-mir-20a, has-miR93 has-, mir3653 has-, mir561 has-, mir200c has-, mir96 has-, mir148a has-, mir1304 has-, mir146b and the other two are not mentioned in the context [PMC8426106]. These findings suggest that aberrant DNA methylation at the promoter of miR183 may play a role in PCa development and progression [PMC5340808]. The dysregulation of these miRNAs could potentially be used as biomarkers for PCa diagnosis and prognosis [PMC8426106]. Further research is needed to fully understand the mechanisms by which these miRNAs regulate gene expression in PCa [PMC8426106].